Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial

BACKGROUND: Enavogliflozin is a novel sodium-glucose cotransporter-2 inhibitor currently under clinical development. This study evaluated the efficacy and safety of enavogliflozin as an add-on to metformin in Korean patients with type 2 diabetes mellitus (T2DM) against dapagliflozin. METHODS: In thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Kyung Ah, Kim, Yong Hyun, Kim, Doo Man, Lee, Byung Wan, Chon, Suk, Sohn, Tae Seo, Jeong, In Kyung, Hong, Eun-Gyoung, Son, Jang Won, Nah, Jae Jin, Song, Hwa Rang, Cho, Seong In, Cho, Seung-Ah, Yoon, Kun Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Diabetes Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695710/
https://www.ncbi.nlm.nih.gov/pubmed/36756676
http://dx.doi.org/10.4093/dmj.2022.0315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695710/
https://www.ncbi.nlm.nih.gov/pubmed/36756676
http://dx.doi.org/10.4093/dmj.2022.0315

Ejemplares similares